Ori Biotech and CTMC Present Scientific Data for New IRO® Platform at ISCT 2024
03. Juni 2024 09:30 ET
|
Ori Biotech Ltd
Ori Biotech and CTMC announce promising results for IRO, Ori’s newly launched next-generation CGT manufacturing enabling platform.
Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene Therapy Conference
29. Mai 2024 15:30 ET
|
Ori Biotech Ltd
Ori Biotech announces the commercial launch of IRO, a next-generation platform built to overcome the challenges of cell therapy manufacturing, at ISCT 2024
Intratumoral Cancer Therapies Market to Observe Stupendous Growth During the Forecast Period (2023–2032), Assesses DelveInsight | Key Players - Nanobiotix, Sirnaomics, Apexigen, Replimune, Merck, OncoSec, DNAtrix, Treovir Istari
15. November 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intratumoral Cancer Therapies Market to Observe Stupendous Growth During the Forecast Period (2023–2032), Assesses DelveInsight | Key Players -...
LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma
24. April 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
First clinical trial seeking to determine if the potentiation of cytotoxic chemotherapy by LB-100 occurs in cancer patients as has been shown in multiple animal studies across a spectrum of cancers ...
LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market
12. April 2022 13:53 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...
Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years
27. Januar 2021 20:30 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively...
Predictive Oncology Inc. CEO Provides Updates on Subsidiaries, Highlights Recent Milestones and Near-Term Goals
27. Oktober 2020 08:30 ET
|
Predictive Oncology
NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology Inc. (NASDAQ: POAI) today announces that its chief executive officer, Carl Schwartz, has been featured in an...
Global Cancer Stem Cell Market to Reach Nearly $2B by 2022
17. Januar 2018 12:29 ET
|
BCC Research
WELLESLEY, Mass., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Cancer stem cells have been found in a range of human tumors and are potential targets for cancer treatment. The global cancer stem cell...